---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-028048"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T13:37:01.797902+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences Q2 net loss $6.4M; cost cuts extend runway into Q1 2024

## Summary
- Net loss of $6.40M ($3.04 per share) vs $2.87M ($2.73) in Q2 2022.
- Cash & equivalents $7.08M at June 30; net cash used in operations $4.47M.
- Cost reduction plan announced to extend financial runway into Q1 2024.
- Multiple USPTO Notices of Allowance for composition of matter claims covering EB-373, EVM201, and EVM301 Series.
- On track to identify EVM301 Series lead candidate by year-end 2023.

## SEC filing metadata
- accession: 0001493152-23-028048
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315223028048/0001493152-23-028048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315223028048/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-028048
- JSON: https://secwatch.observer/filing/0001493152-23-028048.json
- Plain text: https://secwatch.observer/filing/0001493152-23-028048.txt

## Key facts
- Earnings Releases
  Enveric Biosciences, Inc. reported second quarter of 2023 ended June 30, 2023 results: net income $6.40 million, EPS $3.04.
  - Period: second quarter of 2023 ended June 30, 2023
  - Net income: $6.40 million
  - EPS: $3.04
  - Result: reported results
  source text: Net loss attributable to shareholders was $6.40 million for the second quarter ended June 30, 2023, including $1.64 million in net non-cash expenses, with a basic and diluted loss per share of $3.04, as compared to a net loss of $2.87 million and non-cash income of $1.04 million, with primary and diluted loss per share of $2.73 per share for the quarter ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315223028048/0001493152-23-028048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.